FEMASYS INC: management transactions · United States · SEC (Form 4)

About FEMASYS INC

Femasys Inc. (ticker FEMY) is a biomedical and medtech company listed on the NASDAQ in the United States (United States), with a focused franchise in women’s reproductive health. Incorporated in Delaware in 2004 and headquartered in Suwanee, Georgia, near Atlanta, the company addresses a specialized niche that has historically been underserved by large medtech groups. Its strategy is built around minimally invasive, in-office technologies designed to improve diagnosis and treatment in fertility and gynecological care, while reducing reliance on surgery, hormones, implants, or more cumbersome radiology-based procedures. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001339005/000114036126012375/femy-20251231.htm)) Femasys’ product portfolio is anchored by a set of patent-protected devices and product candidates. FemaSeed is positioned as an intratubal insemination solution for female infertility treatment. FemVue and FemCath are used for fallopian tube assessment and related reproductive diagnostics, while FemCerv is designed for endocervical tissue sampling. The company’s most strategically important program is FemBloc, a non-surgical, non-implant, non-hormonal permanent birth control solution that is being advanced through pivotal clinical development. Several of these products are already commercialized in the U.S. and select international markets, and the company has also been expanding its regulatory footprint abroad. ([d5bp8bijhhba2.cloudfront.net](https://d5bp8bijhhba2.cloudfront.net/pdf/55566050e58db1cc44e9f8278a1191a98df3c4bf320038a737406f6388cc3052.pdf)) From a competitive standpoint, Femasys is not a broad-platform healthcare company but a specialist innovator targeting large, underserved global market segments in reproductive health. That focus gives it a differentiated value proposition, particularly for clinicians and patients seeking office-based alternatives that may be simpler, safer, and less invasive than traditional options. At the same time, the company remains in the early-to-mid commercialization phase and carries the execution risks typical of small-cap medtech developers: limited operating history as a commercial business, continuing operating losses, and a dependence on product adoption, clinical progress, and outside financing. The latest annual filing also notes substantial doubt about the company’s ability to continue as a going concern, underscoring the financial risk profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001339005/000114036126012375/femy-20251231.htm)) Recent developments have been important. In 2024, Femasys secured EU MDR / CE Mark certification for multiple products, and it also received additional approvals in the U.K. for FemaSeed and certain diagnostic devices. In 2025, management highlighted clinical, regulatory, and commercial progress, and full-year 2025 revenue increased, primarily due to FemBloc sales. The company also said its cash position would fund operations into the third quarter of 2026 based on its current plan. For international investors, FEMY is therefore best viewed as a high-risk, high-optional-value women’s health platform with meaningful regulatory milestones, early commercialization traction, and a still-constrained balance sheet. ([ir.femasys.com](https://ir.femasys.com/news/news-details/2026/Femasys-Announces-Financial-Results-for-Year-Ended-December-31-2025-and-Provides-Corporate-Update/default.aspx?utm_source=openai))